SDZ 218135
Latest Information Update: 09 Oct 2001
Price :
$50 *
At a glance
- Originator Novartis
- Class Cardiotonics
- Mechanism of Action Sodium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 09 Oct 2001 No-Development-Reported for Heart failure in Switzerland (Unknown route)